Clinical Trial Update: A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma. [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for an anti-PD-L1 antibody combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Anti-PD-L1 antibody (unspecified)

Snippet

Sponsor: Lee's Pharmaceutical Limited | Conditions: Esophageal Cancer | Phase 1, Phase 2 | Status: UNKNOWN